Comments on: Low-Dose Dasatinib for Chronic-Phase CML Safe, Effective With Fewer Adverse Events

Comments on: Low-Dose Dasatinib for Chronic-Phase CML Safe, Effective With Fewer Adverse Events https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/chronic-myeloid-leukemia/low-dose-dasatinib-for-chronic-phase-cml-safe-effective-with-fewer-adverse-events/ Sat, 14 Oct 2023 02:39:46 +0000 hourly 1 https://wordpress.org/?v=6.4.3